ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced that it has received total proceeds of nearly $11.9 million from the exercise of an aggregate of 19,185,965 warrants since the closing of its acquisition of ABcann Medicinals Inc. on April 28, 2017. With these funds, ABcann’s current cash position stands at approximately $45 million, giving the company the means to execute previously outlined plans to expand its production capabilities. “ABcann thanks our shareholders for their continued support and confidence as we work toward expanding our facilities and increasing production,” Aaron Keay, director and CEO of ABcann, stated in the news release. “Our strong financial position, represented by our current cash position is earmarked for new construction and will facilitate the timely execution of our business plan. The Company’s main focus in the coming months will be on the deployment of capital towards the expansion of our existing Vanluven facility and development and construction of the new Kimmett facility, as well as the pursuit of our international expansion plans.”
Read the full article
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Read More
ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Nets Total Proceeds of $11.9 Million from Exercise of Warrants
